News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rhizen Pharmaceuticals S.A. To Present Preclinical Data Of Their First-In-Class Inflammation Assets, RP6503 And RP3128 For Treatment Of Various Respiratory Diseases


9/3/2014 7:19:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

La Chaux-de-Fonds, Switzerland, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces data for their lead first-in-class inflammation/auto-immune assets, RP6503 and RP3128 in preclinical models of pulmonary fibrosis, COPD and asthma. Therapeutic potential of RP3128 in asthma will be highlighted during an oral presentation.

--- Data to be presented at European Respiratory Society (ERS) International Congress 2014, September 6-10, Munich, Germany

--- RP-6503, a novel dual PI3K delta/gamma inhibitor demonstrated potent anti-inflammatory and anti-fibrotic data especially in combination with Esbriet ® (pirfenidone) in preclinical models of pulmonary fibrosis

--- RP-6503, a novel dual PI3K delta/gamma inhibitor demonstrated significant efficacy in preclinical models relevant to COPD

--- Oral administration of RP-3128, a potent and novel CRAC channel inhibitor attenuated respiratory distress in allergen challenged guinea pig models

--- Phase 1 clinical trials (inhalation & oral route) to be initiated in 1H of 2015

Details of the poster and oral presentations:

-- Poster Title: Pre-clinical evaluation of a novel and selective PI3K delta/gamma inhibitor in pulmonary fibrosis

· Session: 160

· Presentation Date & Time: 07 September 2014; 14:45-16:45

· Session Location: Room M-1(B0)

· Poster Board Number: P1507

-- Poster Title: RP-6503, a novel and selective PI3K delta/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD

· Session Information: 160

· Presentation Date & Time: 07 September 2014; 14:45-16:45

· Session Location: Room M-1(B0)

· Poster Board Number: P1504

-- Oral Presentation Title: CRAC channel inhibition by RP3128 ameliorates airway hyper-reactivity in antigen sensitized mice and guinea pigs

· Session: 508

· Presentation Date & Time: 10 September 2014; 10:45-12:45

· Presentation Location: Room 14c (ICM)

About Rhizen Pharmaceuticals S.A.:

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen's website, www.rhizen.com.

CONTACT: Kumar V. Penmetsa, Ph.D. Vice President, Corporate Development Rhizen Pharmaceuticals S.A. Telephone: +1-267-207-5707 Email: kvp@rhizen.com

RhizenL



Hey, check out all the engineering jobs. Post your resume today!

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES